AstraZeneca adds chronic kidney disease TV ad to Farxiga portfolio
AstraZeneca is adding a third arrow to its Farxiga TV ad quiver. Debuting today, the new commercial takes aim at chronic kidney disease, following AZ’s long-time TV advertising of the SGLT2 inhibitor for Type 2 diabetes and more recently heart failure.
Chronic kidney disease (CKD) is on the rise, affecting an estimated one in seven or about 37 million US adults. However, nine out of 10 people with CKD have not been diagnosed, according to data from the CDC.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.